
Pharmacology, RM1-950, autoinflammatory diseases, IL-1 blockade, canakinumab, inflammatory chronic diseases, IL-1 (interleukin-1); IL-1 blockade; anakinra; autoinflammatory diseases; canakinumab; inflammatory chronic diseases; rheumatic diseases, rheumatic diseases, IL-1 (interleukin-1), Therapeutics. Pharmacology, anakinra
Pharmacology, RM1-950, autoinflammatory diseases, IL-1 blockade, canakinumab, inflammatory chronic diseases, IL-1 (interleukin-1); IL-1 blockade; anakinra; autoinflammatory diseases; canakinumab; inflammatory chronic diseases; rheumatic diseases, rheumatic diseases, IL-1 (interleukin-1), Therapeutics. Pharmacology, anakinra
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 3 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
